Eva Bartok Selected Research

Protozoan RNA

1/2019

Human TLR8 Senses RNA From Plasmodium falciparum-Infected Red Blood Cells Which Is Uniquely Required for the IFN-γ Response in NK Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eva Bartok Research Topics

Disease

4	Infections 07/2023 - 10/2015
3	Bites and Stings (Sting) 02/2024 - 10/2022
3	Inflammation (Inflammations) 08/2021 - 03/2011
2	Melanoma (Melanoma, Malignant) 01/2023 - 01/2019
2	Vasculitis (Vasculitides) 12/2022 - 10/2022
2	COVID-19 03/2022 - 01/2022
2	Neoplasms (Cancer) 01/2019 - 04/2017
1	Myotonic Dystrophy (Dystrophia Myotonica) 02/2024
1	Hemorrhage 10/2022
1	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 10/2022
1	Pneumonia (Pneumonitis) 03/2022
1	Neuroinflammatory Diseases 11/2021
1	Atrophy 11/2021
1	Cognitive Dysfunction 11/2021
1	Leukoencephalopathies 11/2021
1	Cutaneous Lupus Erythematosus 08/2021
1	Dermatitis 08/2021
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 11/2019
1	Alcoholic Liver Cirrhosis (Alcoholic Cirrhosis) 11/2019
1	Alcoholic Liver Diseases (Alcoholic Liver Disease) 11/2019
1	Malaria 01/2019
1	Hematologic Diseases (Blood Diseases) 12/2017
1	Neonatal Anemia 12/2017
1	Joint Diseases (Joint Disease) 12/2017
1	Liver Cirrhosis (Hepatic Cirrhosis) 12/2017
1	Membranoproliferative Glomerulonephritis (Membranoproliferative Glomerulonephritis, Type II) 12/2017
1	Carcinogenesis 04/2017
1	Fibrosis (Cirrhosis) 01/2016
1	Vascular System Injuries 08/2011
1	Neointima 08/2011

Drug/Important Bio-Agent (IBA)

4	RNA (Ribonucleic Acid)IBA 07/2023 - 01/2019
4	Antiviral Agents (Antivirals)IBA 07/2023 - 10/2015
3	CytokinesIBA 07/2023 - 01/2019
3	DNA (Deoxyribonucleic Acid)IBA 10/2022 - 10/2015
2	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2023 - 01/2019
2	LigandsIBA 01/2023 - 01/2019
2	Nucleic AcidsIBA 12/2022 - 10/2022
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 10/2022 - 08/2021
2	Neutralizing AntibodiesIBA 03/2022 - 01/2022
2	Immunoglobulin G (IgG)IBA 01/2022 - 11/2020
2	InterferonsIBA 11/2021 - 12/2017
2	Pattern Recognition ReceptorsIBA 01/2021 - 03/2011
2	Proteins (Proteins, Gene)FDA Link 11/2019 - 03/2011
2	Interferon Type IIBA 01/2019 - 10/2015
2	InflammasomesIBA 01/2016 - 08/2011
1	Mitochondrial DNA (mtDNA)IBA 02/2024
1	Viral RNAIBA 07/2023
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 10/2022
1	VaccinesIBA 03/2022
1	OligonucleotidesIBA 03/2022
1	AntigensIBA 01/2021
1	LipidsIBA 11/2019
1	CXC ChemokinesIBA 11/2019
1	Phospholipases (Phospholipase)IBA 11/2019
1	Interleukin-8 (Interleukin 8)IBA 11/2019
1	Protozoan RNAIBA 01/2019
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2019
1	Death Domain ReceptorsIBA 01/2019
1	Antinuclear AntibodiesIBA 12/2017
1	beta-Globins (beta Globin)IBA 04/2017
1	OxalatesIBA 01/2016
1	Adenine FDA LinkGeneric 01/2016
1	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 01/2016
1	NLR ProteinsIBA 08/2011
1	Leucine (L-Leucine)FDA Link 03/2011
1	NucleotidesIBA 03/2011

Therapy/Procedure

2	Immunotherapy 01/2023 - 01/2019
2	Therapeutics 10/2022 - 03/2022
1	Radiotherapy 01/2023